Transcatheter and Surgical Aortic Valve Replacement in Patients With End-Stage Renal Disease

Data on comparative outcomes and readmissions after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with end-stage renal disease (ESRD) are scarce because these patients were excluded from major TAVR trials [(1)][1]. We conducted retrospective